Clinique Rhône Durance
- Address
- 1750 Chemin du Lavarin, 84000 Avignon, France
Clinique Rhône Durance - Cardiovascular Research Center
Clinique Rhône Durance is a specialized cardiovascular research center with expertise in advanced interventional cardiology and antithrombotic therapy management. The center focuses on optimizing treatment strategies for complex patient populations requiring both cardiac interventions and anticoagulation therapy.
- Antithrombotic therapy optimization in patients with atrial fibrillation undergoing percutaneous coronary intervention
- Novel anticoagulation regimens combining P2Y12 inhibitors and direct oral anticoagulants (DOACs)
- Safety and efficacy evaluation of coronary stent procedures in anticoagulated patients
The center actively participates in multinational studies investigating refined approaches to bleeding risk reduction while maintaining cardiovascular protection in patients with atrial fibrillation who require coronary stenting. Their research emphasis on drug-eluting stent technology and simplified antithrombotic regimens demonstrates commitment to improving clinical outcomes and reducing complications in high-risk cardiac populations requiring dual management of thrombotic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Insel Gruppe AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Rhône Durance
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of P2Y12 Inhibitor Monotherapy Followed by Direct Oral Anticoagulant in Atrial Fibrillation Patients Post-Sirolimus-Eluting Stent Implantation | Insel Gruppe AG | Phase III | Recruiting | Dec 2024 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2024-12-16 | 2024-12-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.